OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain

Summary by AI BETAClose X

OKYO Pharma announced new data from its Phase 2 study of urcosimod for neuropathic corneal pain, revealing that patients treated with 0.05% urcosimod showed favorable improvements in corneal nerve fiber count and length, with median increases of +2.0 n/0.16 mm² and +2.6 mm/mm² respectively, compared to median decreases in the placebo group. These exploratory findings, which suggest urcosimod may support corneal nerve restoration, are based on an 18-patient trial and reinforce the company's belief in the therapeutic potential of targeting the chemerin receptor pathway, with a larger Phase 2 trial planned for Q1 2026.

Disclaimer*

UK 100

Latest directors dealings